Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|May 15, 2015
- Pharmaceutical Technology-05-15-2015
- Volume 2015 eBook
- Issue 2
Disposable Technology versus Traditional Stainless Steel--When Time Means Money
Author(s)Susanne Resatz, PhD
The use of disposables requires careful consideration and planning.
Advertisement
Disposables offer many advantages in clinical manufacturing, such as speeding up time-to-clinic by preventing the need for cleaning validation. In addition, precious API that are often in short supply during early development can be saved. The use of disposables, however, requires careful consideration and planning.
Download
Articles in this issue
over 11 years ago
Validating and Implementing a Rapid Sterility Testing Methodover 11 years ago
Cleanroom and Facility Planning: Getting Beyond Cost Per Square Footover 11 years ago
Aging Facilities: Aseptic Manufacturing Faces the FutureAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement